2CUREX AB SEK-10 Total Liabilities
2CUREX AB SEK-10 total liabilities. Based on the latest financial reports, 2CUREX AB SEK-10 (2QE) has total liabilities worth €4.55 Million EUR (≈ $5.32 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of 2CUREX AB SEK-10 to measure how many days the company can operate on defensive assets alone.
Total Liabilities of 2CUREX AB SEK-10 (2021–2024)
Total liabilities of 2CUREX AB SEK-10 from 2021 to 2024. This chart illustrates how 2CUREX AB SEK-10's total liabilities have evolved over time, based on quarterly financial data.
2CUREX AB SEK-10 Competitors by Total Liabilities
The table below lists competitors of 2CUREX AB SEK-10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Satis Group S.A.
WAR:STS
|
Poland | zł274.74 Million |
|
Applied DNA Sciences, Inc.
NASDAQ:BNBX
|
USA | $1.50 Million |
|
Lyc Healthcare Bhd
KLSE:0075
|
Malaysia | RM216.25 Million |
|
Braemar Plc
LSE:BMS
|
UK | GBX69.89 Million |
|
Pacific Bay Minerals Ltd
V:PBM
|
Canada | CA$688.59K |
|
PENTIXAPHARM HOLDING N AG
XETRA:PTP
|
Germany | €10.04 Million |
|
Alveen
PA:MLALV
|
France | €792.00K |
|
Cake Box Holdings PLC
LSE:CBOX
|
UK | GBX36.08 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down 2CUREX AB SEK-10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 2QE current and non-current assets.
Liquidity & Leverage Metrics
2CUREX AB SEK-10 Total Liabilities Ratios Explained
2CUREX AB SEK-10 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 2CUREX AB SEK-10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 2CUREX AB SEK-10 (2021–2024)
The table below shows the annual total liabilities of 2CUREX AB SEK-10 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €3.03 Million ≈ $3.54 Million |
+467.73% |
| 2023-12-31 | €533.00K ≈ $623.13K |
-88.47% |
| 2022-12-31 | €4.62 Million ≈ $5.40 Million |
-4.01% |
| 2021-12-31 | €4.82 Million ≈ $5.63 Million |
-- |
About 2CUREX AB SEK-10
2cureX AB (publ) operates as a medical technology company in Europe. ts proprietary IndiTreat test family creates various three-dimensional tumoroids derived from fresh samples of colorectal cancer (CRC) tissue that has been obtained from an individual patient's metastatic colorectal cancer. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.